Formula I Nucleoside Analog Inhibits Viral Polymerase
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Arenaviridae virus infections, such as Lassa and Junin viruses, lack effective therapies, and existing methods for Coronaviridae viruses like SARS and MERS do not provide sufficient therapeutic options, leading to high morbidity and mortality rates.
Innovation Solution
Administration of a therapeutically effective amount of a compound of Formula I or its pharmaceutically acceptable salt/ester, which inhibits Arenaviridae and Coronaviridae RNA-dependent RNA polymerase, thereby treating infections caused by these viruses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If no approved therapy is administered for Lassa virus infection, then the virus replicates unchecked causing high mortality rates, but administering existing treatments like ribavirin does not provide sufficient therapeutic efficacy
Solution Approach 1:
The patent modifies the chemical structure of ribavirin by replacing the ribose sugar moiety with various cyclic and acyclic carbon-based structures (Formula I compounds). This structural parameter change creates analogs with improved antiviral activity against Lassa virus and other Arenaviridae/Coronaviridae infections, overcoming the limitations of conventional ribavirin therapy
Solution Approach 2:
The invention creates synthetic analogs (copies) of ribavirin with modified chemical structures that retain the core triazine ring system but incorporate improved pharmacological properties. These copied structures demonstrate enhanced therapeutic efficacy while maintaining the mechanism of action against viral RNA polymerase
2Reliability
If conventional treatments are used for Coronaviridae infections, then some symptomatic relief may be provided, but effective therapies are lacking leading to high morbidity and mortality
Solution Approach 1:
The patent applies structural modifications to create Formula I compounds that exhibit broad-spectrum activity against Coronaviridae viruses including SARS and MERS. The modified chemical parameters (cyclic vs acyclic carbon structures, various substituent groups) enhance viral replication inhibition compared to conventional treatments
Solution Approach 2:
The Formula I compounds demonstrate multi-functionality by effectively treating infections from multiple virus families (Arenaviridae and Coronaviridae). This universal antiviral activity arises from the compounds' ability to inhibit RNA-dependent RNA polymerase across different viral systems, providing a broad-spectrum therapeutic solution
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound effectively treats Arenaviridae and Coronaviridae infections by inhibiting viral replication, reducing morbidity and mortality associated with these viruses.
Implementation Method 1
a compound of Formula I or a pharmaceutically acceptable salt or ester thereof which inhibits Arenaviridae and Coronaviridae RNA-dependent RNA polymerase
Data Source
Figure 1
Figure 2A~2B
Figure 3A~3F
AI summary
Provided are methods for treating Coronaviridae virus infections by administering nucleosides and prodrugs thereof, of Formula I: wherein the 1' position of the nucleoside sugar is substituted.